
CLAIMS:

1. A compound of Formula (I)



(I),

or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof,

wherein

X is independently selected from N or CH;


p is an integer selected from 1 or 2;

v is an integer selected from 1 or 2;

m is an integer selected from 1, 2, or 3;

n is an integer selected from 0, 1, or 2;

t is an integer selected from 1 or 2;

Ring A is  , wherein **2 refers to the position attached to phenyl;

Ring B is an aryl or 5- or 6- membered heteroaryl;

L^2 is a direct bond, $-(CR^aR^b)_q-$, -O-, -S-, -S(O)-, $-SO_2-$, -C(O)-, C(O)O-, -OC(O)-, $-NR^a-$, $-C(O)NR^a-$, $-NR^aC(O)-$, $-NR^aC(O)O-$, $-NR^aC(O)NR^b-$, $-SO_2NR^a-$, $-NR^aSO_2-$, $-NR^aS(O)_2NR^b-$, $-NR^aS(O)NR^b-$, $-C(O)NR^aSO_2-$, $-C(O)NR^aSO-$, $-C(=NR^a)NR^b-$, or cycloalkyl, wherein q is a number of 1 to 7;

R^{11} is $-C_{1-3}$alkyl, $-C_{3-10}$cycloalkyl, aryl, 5- or 6- membered monocyclic heteroaryl, 7- to 10-membered bicyclic heteroaryl, 3- to 6-membered monocyclic heterocyclyl, 7- to 14-membered bicyclic heterocyclyl, each of which is independently optionally substituted with 1, 2, 3 or 4 substituents R^{11X},

R^{11X}, at each occurrence, is independently halogen, $-C_{1-8}$alkyl, haloC_{1-8}alkyl, $-C_{2-8}$alkenyl, -

C_{2-8}alkynyl, -C_{3-8}cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, -CN, -NO_2, -OR^{11a}, -SO_2R^{11a}, -COR^{11a}, -CO_2R^{11a}, -$CONR^{11a}R^{11b}$, -$C(=NR^{11a})NR^{11b}R^{11c}$, -$NR^{11a}R^{11b}$, -$NR^{11a}COR^{11b}$, -$NR^{11a}CONR^{11b}R^{11c}$, -$NR^{11a}CO_2R^{11b}$, -$NR^{1a}SONR^{11b}R^{11c}$, -$NR^{11a}SO_2NR^{11b}R^{11c}$, -$P(=O)R^{11a}R^{11b}$, or –$NR^{11a}SO_2R^{11b}$, wherein said C_{3-8}cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with halogen, -C_{1-8}alkyl, -haloC_{1-8}alkyl, -C_{1-8}alkoxyl, or -haloC_{1-8}alkoxyl;

R^{11a}, R^{11b}, and R^{11c} are each independently hydrogen, -C_{1-8}alkyl, -haloC_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl, -C_{3-8}cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein said C_{3-8}cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with halogen, -C_{1-8}alkyl, -haloC_{1-8}alkyl, -C_{1-8}alkoxyl, or -haloC_{1-8}alkoxyl;

R^{12} is hydrogen, halogen, -C_{1-8}alkyl, haloC_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl, -C_{3-8}cycloalkyl, heterocyclyl, aryl, heteroaryl, -oxo, -CN, -NO_2, -OR^{1a}, -SO_2R^{1a}, -COR^{1a}, -CO_2R^{1a}, -$CONR^{1a}R^{1b}$, -$C(=NR^{1a})NR^{1b}R^{1c}$, -$NR^{1a}R^{1b}$, -$NR^{1a}COR^{1b}$, -$NR^{1a}CONR^{1b}R^{1c}$, -$NR^{1a}CO_2R^{1b}$, -$NR^{1a}SONR^{1b}R^{1c}$, -$NR^{1a}SO_2NR^{1b}R^{1c}$, or –$NR^{1a}SO_2R^{1b}$;

R^{1a} and R^{1b}, are each independently hydrogen, -C_{1-8}alkyl, -haloC_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl;

R^{1c} is hydrogen, -C_{1-8}alkyl, -haloC_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl;

R^2 is independently selected from halogen, -C_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl or -C_{3-6}cycloalkyl; wherein said -C_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl or -C_{3-6}cycloalkyl are each independently optionally substituted with halogen, hydroxy, C_{1-6}alkoxy, or amino, -C_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl, C_{3-6}cycloalkyl or C_{3-6}heterocyclyl;

R^3 is –L^1-CyC,

wherein

L^1 is a direct bond, -$(CR^aR^b)_{1-4}$-, -O-$(CR^aR^b)_{0-3}$-, -NH-$(CR^aR^b)_{1-3}$, -$NHC(O)NR^a$-$(CR^aR^b)_{1-3}$, or -NH-;

CyC is cycloalkyl, or heterocyclyl, each of which is optionally substituted with one, two, three or four substituents R^{3a};

R^{3a} is independently selected from hydrogen, halogen, cyano, oxo, -OR^{3b}, -$NR^{3b}R^{3c}$, -COR^{3b}, -SO_2R^{3b}, -C_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl, -cycloalkyl, or heterocyclyl, each of said -C_{1-8}alkyl, and heterocyclyl is optionally substituted with one, or two substituents R^{3e} which is selected from hydrogen, halogen, cyano, -OR^{3f}, -C_{1-8}alkyl, -cycloalkyl, or heterocyclyl;

wherein R^{3b}, and R^{3c} are each independently hydrogen, -C_{1-8}alkyl, -cycloalkyl, or heterocyclyl, said -C_{1-8}alkyl is optionally substituted with one or two substituents R^{5e} which is hydrogen, -$NR^{3f}R^{3g}$, -cycloalkyl, or heterocyclyl;

R^{3f} and R^{3g} are each independently hydrogen or -C_{1-8}alkyl;

or, two adjacent R^3 on the phenyl ring together with the phenyl ring form a benzo ring, said ring is optionally substituted with heteroaryl;

R^a and R^b are independently hydrogen, -C_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl; and,

R^4 and R^5 are each independently hydrogen, halogen, cyano, $-NO_2$, $-C_{1-8}$alkyl, $-C_{2-8}$alkenyl, or $-C_{2-8}$alkynyl.

2. The compound of claim 1, wherein X is N; ring B is phenyl, furanyl, isoxazolyl, pyridinyl, pyrazolyl, or pyrimidinyl; wherein R^2 is halo, $-C_{1-6}$alkyl or $-C_{3-4}$cycloalkyl; wherein said $-C_{1-6}$alkyl and $-C_{3-4}$cycloalkyl are each independently optionally substituted with hydrogen, $-C_{1-3}$alkyl, C_{3-6}cycloalkyl or C_{3-6}heterocyclyl; and n is 0, and L^2 is $-(CH_2)_q-$, or -O-, wherein q is a number of 1-3.

3. The compound of claim 1, wherein R^2 is fluoro, methyl, isopropyl, isobutyl, cyclopropyl, cyclobutyl or morpholinomethyl.

4. The compound of claim 1, wherein R^{11} is $-C_{3-10}$cycloalkyl, aryl, 5- or 6- membered monocyclic heteroaryl, 7- to 10-membered bicyclic heteroaryl, 3- to 6-membered monocyclic heterocyclyl, 7- to 14-membered bicyclic heterocyclyl, each of which is independently optionally substituted with 1, 2, or 3 substituents R^{11X}, wherein R^{11X} is defined as with formula (I).

5. The compound of claim 4, wherein

a) R^{11} is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or 3- to 6 membered heterocycloalkyl containing 1 or 2 heteroatoms selected from oxygen and nitrogen atoms; or

b) R^{11} is cyclohexyl, bicyclo[1.1.1]pentanyl, tetrahydro-2H-pyran-1-yl, tetrahydro-2H-pyran-2-yl, tetrahydro-2H-pyran-3-yl, tetrahydro-2H-pyran-4-yl oxazol-2-yl, oxazol-4-ylmethyl or oxazol-5-yl; or

c) R^{11} is phenyl or 8- to 10-membered bicyclic aryl, optionally substituted with 1 to 2 substituents R^{11X}; or

d) R^{11} is cyclohexyl, 4-methoxylcyclohexyl, bicyclo[1.1.1]pentan-1-yl, tetrahydro-2H-pyran-4-yl, oxazol-4-yl, phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 4-chlorophenyl, 2,4-difluorophenyl, 3,5-difluorophenyl, 3,4-difluorophenyl, 4-cyanophenyl, 4-methylphenyl, 4-(trifluoromethyl)phenyl, 2-methoxylphenyl, 3-methoxylphenyl, 4-methoxylphenyl, 4-ethoxylphenyl, 4-methoxylphenyl, 4-(trifluoromethoxyl)phenyl, 2,4-dimethoxylphenyl, 2,3-dimethoxylphenyl, 3,4-dimethoxylphenyl, 3,5-dimethoxylphenyl, 3,4,5-trimethoxylphenyl, chroman-6-yl, chroman-4-yl, 2,3-dihydrobenzo[b][1,4]dioxin-6-yl, 2,3-dihydrobenzo[b][1,4]dioxin-5-yl, or 5,6,7,8-tetrahydronaphthalen-2-yl, or 5,6,7,8-tetrahydronaphthalen-1-yl; or

e) R^{11} is furanyl, isoxazolyl, pyridinyl, pyrazolyl, pyrimidinyl, benzo[b]thiophenyl or benzofuranyl.

6. The compound of claim 5, wherein

(i) R^{11} is chromanyl, benzo[b][1,4]dioxinyl,5,6,7,8-tetrahydronaphthalenyl, octahydro-5H-2,5-methanoindenyl, 2,3,4,5-tetrahydrobenzo[b]oxepinyl, adamantanyl, each of which is optionally substituted with 1 or 2 R^{11X}; or

(ii) R^{11} is furan-2-yl, isoxazol-4-yl, pyridin-3-yl, pyridin-2-yl, 1H-pyrazol-4-yl, pyrimidin-2-yl, benzo[b]thiophen-5-yl, benzo[b]thiophen-4-yl, benzofuran-5-yl, or benzofuran-4-yl; or

(iii) R^{11} is phenyl substituted with cyano, fluoro, chloro, bromo, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, difluoromethyl, trifluoromethyl, trifluoromethoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetan-3-yl, cyclopropoxy, cyclobutoxy, cyclopentoxy, cyclohexoxy, $-NH_2$, or $-NH(CH_3)$.

7. The compound of any one of claims 4-6, wherein R^{11X} is halogen, cyano, hydroxy, $-C_{1-8}$alkyl, haloC_{1-8}alkyl, $-C_{2-8}$alkenyl, $-C_{2-8}$alkynyl, C_{1-6}alkoxyl, haloC_{1-6}alkoxyl, C_{3-6}cycloalkyl, heterocyclyl, C_{3-}

$_6$cycloalkoxyl, -NH_2, -$NH(C_{1-8}alkyl)$, -$N(C_{1-8}alkyl)_2$ or heterocyclyl-O-.

8. The compound of claim 4, wherein

a) R^{11}-L^2- is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or 1,2,3,4-tetrahydronaphthalen-1-yl, 3-phenylcyclobut-1-yl, 3-phenylcyclopent-1-yl, 4-phenylcyclohex-1-yl or 3-(4-methoxylphenyl)cyclopent-1-yl; or


b) R^{11}-L^2- is a 3- to 6-membered monocyclic heterocyclyl selected from oxetanyl, tetrahydrofuranyl, or tetrahydro-2H-pyranyl; or

c) R^{11}-L^2- is selected from furan-2-ylmethyl, isoxazol-4-ylmethyl, (pyridin-3-yl)methyl, (6-methoxypyridin-3-yl)methyl, (5-methoxypyridin-2-yl)methyl, (1-methyl-1H-pyrazol-4-yl)methyl, (3-methoxy-1-methyl-1H-pyrazol-4-yl)methyl, (1-cyclopropyl-1H-pyrazol-4-yl)methyl, (5-methoxypyrimidin-2-yl)methyl, benzo[b]thiophen-5-ylmethyl, benzo[b]thiophen-4-ylmethyl, benzofuran-5-ylmethyl, or benzofuran-4-ylmethyl.

9. The compound of claim 1, wherein L^2 is -SO_2- or -CO-, and R^{11} is -C_{1-3}alkyl or phenyl, each of which is optionally substituted with C_{1-3}alkoxyl.

10. The compound of claim 1, wherein m is 1, R^3 is –L^1-CyC, and L^1 is a direct bond, -$(CH_2)_{0-2}$-, -$N(CH_2)_{0-2}$, or -$O(CH_2)_{0-2}$.

11. The compound of claim 1, wherein CyC is

a) cycloalkyl selected from monocyclic C_{3-8}cycloalkyl or bridged cycloalkyl (), each of which is optionally substituted with one or two substituents R^{3a}; or

b) heterocyclyl selected from monocyclic 4 to 9-membered heterocyclyl groups containing one nitrogen or oxygen or sulfur heteroatom as ring member; monocyclic 4 to 9-membered heterocyclyl groups containing two heteroatoms selected from oxygen, sulfur, and nitrogen as ring members, which is optionally substituted with one, two, three or four substituents R^{3a}; or

c) 5- to 10-membered spiro heterocyclyl comprising one or two heteroatoms selected from nitrogen, sulfur, and oxygen as ring members, which is optionally substituted with one, two, three or four substituents R^{3a}; or

d) 5- to 10-membered bridged heterocyclyl comprising one or two heteroatoms selected from nitrogen, sulfur, and oxygen as ring members, which is optionally substituted with one, two, three or four substituents R^{3a}; or

e) a monocyclic 6-membered heterocyclyl group containing two heteroatoms selected from oxygen and nitrogen as ring members; or

f) 4-membered/4-membered, 3-membered/5-membered, 4-membered/5-membered, 4-membered/6-membered, 5-membered/5-membered, or 5-membered/6-membered mono-spiro heterocyclyl comprising one or two nitrogen or oxygen as ring members.

12. The compound of claim 11, wherein CyC is

(i) cyclobutyl, cyclopentyl or cyclohexyl, each of which is optionally substituted with one or two substituents R^{3a}; or



(ii) a monocyclic 4 to 6-membered heterocyclyl groups containing one nitrogen or oxygen or sulfur heteroatom as the ring members; or

(iii) oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, and piperdinyl;

(iv) dioxanyl, morpholino, morpholinyl, or piperzinyl; or

(v) 1,3-dioxan-2-yl, 1,3-dioxan-4-yl, 1,4-dioxan-2-yl, morpholin-1-yl, morpholin-2-yl, or morpholin-3-yl.

13. The compound of claim 12, wherein CyC is selected from oxetan-2-yl, Oxetan-3-yl, tetrahydrofuran-4-yl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydropyran-2-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, azetidin-3-yl, azetidin-2-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperdin-4-yl, piperdin-2-yl, and piperdin-3-yl.

14. The compound of claim 11, wherein CyC is  (7-oxa-2-azaspiro[3.5]nonan-2-yl), or  (2-oxaspiro[3.5]nonan-7-yl).

15. The compound of claim 14, wherein R^{3a} is independently selected from hydrogen, halogen, cyano, oxo, $-OR^{3b}$, $-NR^{3b}R^{3c}$, $-C(=O)R^{3b}$, $-SO_2R^{3b}$, $-C_{1-6}$alkyl, monocyclic C_{3-6}cycloalkyl, or monocyclic 4 to 9-membered heterocyclyl group containing one or two heteroatoms selected from nitrogen or oxygen or sulfur heteroatom as ring members, each of said $-C_{1-6}$alkyl and monocyclic 4 to 9-membered heterocyclyl group is optionally substituted with one or two substituents R^{3e}.

16. The compound of claim 15, wherein

a) R^{3a} is C_{3-6}cycloalkyl; or

b) R^{3a} is 4 to 6-membered heterocyclyl groups containing one or two heteroatoms selected from nitrogen or oxygen or sulfur heteroatom as ring members; or

c) R^{3a} is oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, piperzinyl, or morpholinyl; or

d) R^{3a} is oxetan-3-yl, tetrahydrofuran-3-yl, tetrahydro-2H-pyran-4-yl, or morphin-4-yl; or

e) R^{3e} is monocyclic 4 to 9-membered heterocyclyl group containing one or two heteroatoms selected from nitrogen or oxygen or sulfur heteroatom as ring members; or

f) R^{3e} is tetrahydro-pyran-4-yl; or

g) R^{3a} is $-NR^{3b}R^{3c}$, wherein R^{3b} is hydrogen, and R^{3c} is heterocyclyl; or

h) R^{3a} is $-NR^{3b}R^{3c}$, wherein R^{3b} is hydrogen, and R^{3c} is tetrahydro-pyran-4-yl; or

i) R^{3a} is $-NR^{3b}R^{3c}$, wherein R^{3b} and R^{3c} are each independently hydrogen or $-C_{1-6}$alkyl substituted with cycloalkyl; or

j) R^{3a} is $-OR^{3b}$ or $-SO_2R^{3b}$, wherein R^{3b} is hydrogen or C_{1-8}alkyl; or

k) R^{3a} is $-COR^{3b}$, wherein R^{3b} is hydrogen or C_{1-6}alkyl optionally substituted with $-NR^{3f}R^{3g}$, wherein R^{3f} and R^{3g} are each independently hydrogen or C_{1-6}alkyl.

17. The compound of any one of claims 1-16,

q is 1; or

R^{11} is octahydro-5H-2,5-methanoinden-5-yl, 2,3,4,5-tetrahydrobenzo[b]oxepin-7-yl, or adamantan-1-yl, or

R^{11}-L^2- is oxetan-3-yl, tetrahydrofuran-3-yl, and tetrahydro-2H-pyran-4-yl, or


R^{3a} is cyclopropyl, or -$NR^{3b}R^{3c}$, or


R^{3a} is -$NR^{3b}R^{3c}$, R^{3b} and R^{3c} are each independently hydrogen or–$C_{1\text{-}6}$alkyl substituted with monocyclic $C_{3\text{-}6}$cycloalkyl, or

R^{3a} is -COR^{3b}, wherein R^{3b} is hydrogen or $C_{1\text{-}6}$alkyl optionally substituted with -$NR^{3f}R^{3g}$, wherein R^{3f} and R^{3g} are each independently hydrogen or methyl.

18. The compound of claim 1, wherein two adjacent R^3 on the phenyl ring together with the phenyl ring form indazolyl which is substituted with tetrahydropyranyl.

19. The compound of claim 1, wherein m is 1 and R^3 is selected from the group consisting of:







20. The compound of claim 1, wherein R^4 is halogen selected from fluoro (-F), chloro (-Cl) or bromo (-Br).

21. The compound of claim 1, wherein R^4 is at position 3 of the pyrrolo[2,3-b]pyridin-5-yl ring.


22. The compound of claim 1, wherein the compound is selected from the group consisting of:




(Ex. 2);




(Ex. 3a) and (Ex. 3b);




(Ex. 4);




(Ex. 5);




(Ex. 6);




or




(Ex. 6a) and (Ex. 6b);




(Ex. 7);




(Ex. 8);




(Ex. 9);




(Ex. 10);




(Ex. 11);




(Ex. 12);




(Ex. 13);




or




(Ex. 13a) and (Ex. 13b);




(Ex. 14);




(Ex. 15);




(Ex. 16);




(Ex. 17);




(Ex. 18);





(Ex. 19);





or





(Ex. 19a);


 or  (Ex. 19b);


 (Ex. 20);


 (Ex. 21);


 (Ex. 22);


 (Ex. 22a) and (Ex. 22b);


 (Ex. 23);

 (Ex. 24a) and (Ex. 24b);


 (Ex. 25a) and (Ex. 25b);

 (Ex. 26);


 (Ex. 27);




(Ex. 28);




or




(Ex. 28a);




(Ex. 29);




or




(Ex. 29a);




(Ex. 30);




(Ex. 31);




or




(Ex. 32);




or





(Ex. 33);





(Ex. 34);



(Ex. 35);



(Ex. 36);



(Ex. 37);



(Ex. 38);



(Ex. 39);



(Ex. 40);



(Ex. 41);



(Ex. 42);


(Ex. 43);



(Ex. 44);


(Ex. 45);



(Ex. 46);




(Ex. 47);




(Ex. 48);




or




(Ex. 48a);




(Ex. 49);




(Ex. 50);




(Ex. 51);




(Ex. 52);




or




(Ex. 52a);




(Ex. 53);




(Ex. 54);




(Ex. 55);




(Ex. 56);




(Ex. 57);




(Ex. 58);




(Ex. 59);




(Ex. 60);




(Ex. 61);




(Ex. 62);




(Ex. 63);




(Ex. 64a) and (Ex. 64b);




(Ex. 65);




(Ex. 66);




(Ex. 67);




(Ex. 68);




or




(Ex. 69);




(Ex. 70);




(Ex. 71);




(Ex. 72);




(Ex. 73);




(Ex. 74);





(Ex. 75);





(Ex. 76);



(Ex. 77);



(Ex. 78);



(Ex. 79);



(Ex. 79a);



(Ex. 79b);



(Ex. 80a) and (Ex. 80b);



(Ex. 81);


(Ex. 81a);



(Ex. 81b);


(Ex. 82);



(Ex. 83);




or




(Ex. 84);




or




(Ex. 85);




or




(Ex. 86);




or




(Ex. 87);




or




(Ex. 88);




or




(Ex. 89);




or




(Ex. 90);




or




(Ex. 91);




or




(Ex. 92);




or




(Ex. 93);




or




(Ex. 94);




or




(Ex. 95);




(Ex. 96);




(Ex. 97);




(Ex. 98);




(Ex. 99);




(Ex. 100);




(Ex. 101);




(Ex. 102);




(Ex. 103);




(Ex. 104);




(Ex. 105);




(Ex. 106);




(Ex. 107);




(Ex. 108);




(Ex. 109);




(Ex. 110), (Ex. 111) and (Ex. 112);




(Ex. 113);




(Ex. 114);




(Ex. 115);




(Ex. 116);




(Ex. 117);




(Ex. 118);




(Ex. 119);




(Ex. 120);




(Ex. 121);




(Ex. 121a);




(Ex. 122);




(Ex. 123);




(Ex. 124);




(Ex. 125);





(Ex. 126);





(Ex. 127);



(Ex. 128);



(Ex. 129);



(Ex. 130);



(Ex. 131);



(Ex. 132);



(Ex. 133);



(Ex. 134);


(Ex. 135);



(Ex. 136);


(Ex. 137);



(Ex. 138);




(Ex. 139);




(Ex. 140);




(Ex. 141a);




(Ex. 141b);




(Ex. 142);




(Ex. 143);




(Ex. 144);




(Ex. 145);




(Ex. 146);




(Ex. 147);




(Ex. 148);




(Ex. 149a);




(Ex. 149b);




(Ex. 150);




(Ex. 151);




(Ex. 152);




(Ex. 153);




(Ex. 154);




(Ex. 155);





(Ex. 156);





(Ex. 157);



(Ex. 158);



(Ex. 159);



(Ex. 160);



(Ex. 161);



(Ex. 162);



(Ex. 163);



(Ex. 164);



(Ex. 165);



(Ex. 166);



(Ex. 167);



(Ex. 168);



(Ex. 169);



(Ex. 170);



(Ex. 171);



(Ex. 172);



(Ex. 173);



(Ex. 174);



(Ex. 175);


(Ex. 176);



(Ex. 177);


(Ex. 178);



(Ex. 179);




(Ex. 180);




(Ex. 181);




(Ex. 182);




(Ex. 183);




(Ex. 184);




(Ex. 185);




(Ex. 186);




(Ex. 187);




(Ex. 188);




(Ex. 189);




(Ex. 190);




(Ex. 191);




(Ex. 192);




(Ex. 193);




(Ex. 194);




(Ex. 195);




(Ex. 196);




(Ex. 197);




(Ex. 198);




(Ex. 199);




(Ex. 200);




(Ex. 201);




(Ex. 202);




(Ex. 203);




(Ex. 204);




(Ex. 205);




(Ex. 206);




(Ex. 207);




(Ex. 208);




(Ex. 209);




(Ex. 210);





(Ex. 211);





(Ex. 212);



(Ex. 213);



(Ex. 214);



(Ex. 215);



(Ex. 216);



(Ex. 217);



(Ex. 218);



(Ex. 219);


(Ex. 220);



(Ex. 221);


(Ex. 222);



(Ex. 223);




(Ex. 224);




(Ex. 225) and (Ex. 226);




(Ex. 227);




(Ex. 228);




(Ex. 229);




(Ex. 230);




(Ex. 231);




(Ex. 232);




(Ex. 233);




(Ex. 234);




(Ex. 235);




(Ex. 236) and (Ex. 237);




(Ex. 238);




(Ex. 239);




(Ex. 240);




(Ex. 241);




(Ex. 242);




(Ex. 243);




(Ex. 244);




(Ex. 245);




(Ex. 246);




(Ex. 247);




(Ex. 248);




(Ex. 249);




(Ex. 250);




(Ex. 251);




(Ex. 252);




(Ex. 253);




(Ex. 254);




(Ex. 255);




(Ex. 256);





(Ex. 257);





(Ex. 258);



(Ex. 259);



(Ex. 260);



(Ex. 261);



(Ex. 262);



(Ex. 263);



(Ex. 264);



(Ex. 265);



(Ex. 266);



(Ex. 267);



(Ex. 268);



(Ex. 269);



(Ex. 270);



(Ex. 271);



(Ex. 272);



(Ex. 273);



(Ex. 274);



(Ex. 275);



(Ex. 276);


(Ex. 277);



(Ex. 278);


(Ex. 279);



(Ex. 280);




(Ex. 281);




(Ex. 282);




(Ex. 283);




(Ex. 284);




(Ex. 285);




(Ex. 286);




(Ex. 287);




(Ex. 288);




(Ex. 289);





(Ex. 290);





(Ex. 291);



(Ex. 292);



(Ex. 293);



(Ex. 294);



(Ex. 295);



(Ex. 296);



(Ex. 297);



(Ex. 298);



(Ex. 299);



(Ex. 300);



(Ex. 301);



(Ex. 302);



(Ex. 303);



(Ex. 304);



(Ex. 305);



(Ex. 306);



(Ex. 307);



(Ex. 308);



(Ex. 309);



(Ex. 310);



(Ex. 311);



(Ex. 312);



(Ex. 313);



(Ex. 314);



(Ex. 315);



(Ex. 316);



(Ex. 317);



(Ex. 318);



(Ex. 319);



(Ex. 320);



(Ex. 321);



(Ex. 322);



(Ex. 323);



(Ex. 324);



(Ex. 325);



(Ex. 326);



(Ex. 327);



(Ex. 328);



(Ex. 329);



(Ex. 330);



(Ex. 331);



(Ex. 332);



(Ex. 333);



(Ex. 334);



(Ex. 335);



(Ex. 336);



(Ex. 337);



(Ex. 338);



(Ex. 339);



(Ex. 340);



(Ex. 341);



(Ex. 342);



(Ex. 343);



(Ex. 344);



(Ex. 345);



(Ex. 346);



(Ex. 347);



(Ex. 348);



(Ex. 349);



(Ex. 350);



(Ex. 351);



(Ex. 352);


(Ex. 353);



(Ex. 354);


(Ex. 355);



(Ex. 356);




(Ex. 357);




(Ex. 358);




(Ex. 359);




(Ex. 360);




(Ex. 361);




(Ex. 362);




(Ex. 363);




(Ex. 364);




(Ex. 365);




(Ex. 366);




(Ex. 367);




(Ex. 368);



(Ex. 369);



(Ex. 370); or



(Ex. 371).

23. A pharmaceutical composition, comprising the compound of any one of claims 1-22 or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, and at least one of pharmaceutically acceptable excipients.

24. Use of the compound of any one of claims 1-23, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof in the manufacture of a medicament for treating dysregulated apoptotic diseases.

25. The use of claim 24, wherein the dysregulated apoptotic disease is a neurodegenerative condition, proliferative diseases, and pro-thrombotic conditions.